Inogen, Inc (NASDAQ:INGN – Get Free Report) EVP Boyer Jennifer Yi sold 10,770 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $6.53, for a total transaction of $70,328.10. Following the completion of the sale, the executive vice president owned 15,977 shares in the company, valued at $104,329.81. The trade was a 40.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Inogen Trading Up 5.5%
Shares of NASDAQ:INGN opened at $6.31 on Friday. The firm’s 50 day moving average is $6.59 and its two-hundred day moving average is $6.47. Inogen, Inc has a 52 week low of $5.34 and a 52 week high of $9.13. The firm has a market capitalization of $170.87 million, a P/E ratio of -6.93 and a beta of 1.60.
Inogen (NASDAQ:INGN – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The medical technology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.06). Inogen had a negative net margin of 7.08% and a negative return on equity of 12.90%. The firm had revenue of $85.11 million during the quarter, compared to analyst estimates of $82.35 million. Analysts predict that Inogen, Inc will post -0.77 EPS for the current year.
Wall Street Analyst Weigh In
View Our Latest Research Report on Inogen
Institutional Investors Weigh In On Inogen
Several hedge funds and other institutional investors have recently added to or reduced their stakes in INGN. Quarry LP bought a new stake in Inogen during the fourth quarter worth approximately $27,000. Torren Management LLC acquired a new position in Inogen in the fourth quarter worth approximately $51,000. Prelude Capital Management LLC acquired a new position in Inogen in the third quarter worth approximately $82,000. Corient Private Wealth LLC acquired a new position in Inogen in the fourth quarter worth approximately $84,000. Finally, MetLife Investment Management LLC grew its position in Inogen by 72.2% in the fourth quarter. MetLife Investment Management LLC now owns 12,699 shares of the medical technology company’s stock worth $85,000 after buying an additional 5,325 shares during the last quarter. Institutional investors own 89.94% of the company’s stock.
About Inogen
Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.
Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.
Read More
- Five stocks we like better than Inogen
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.
